Ibrutinib, an inhibitor of Bruton's tyrosine kinase, has been approved for the treatment of chronic lymphocytic leukemia, MCL, Waldenström's macroglobulinemia, etc. It is a promising new antitumor drug. This evidence concerns the gene BTK and Waldenstrom macroglobulinemia.